Good morning, and welcome to today's conference call for Omeros Corporation. At this time, all participants are in listen-only mode. After the Company's remarks, we will conduct a question-and-answer session. Please be advised that this call is being recorded at the Company's request and a replay will be available on the Company's website for one week from today. I'll turn over the call to Mark Metcalf at Omeros.

Good morning, and thank you for joining the call today. I'd like to remind you that some of the statements that will be made on the call today will be forward-looking. These statements are based on management's beliefs and expectations as of today only and are subject to change. All forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially. Please refer to the risk factors section of the Company's filings with the SEC for a discussion of these risks and uncertainties. Now, I would like to turn the call over to Dr. Greg Demopulos, Chairman and CEO of Omeros.

Thank you, Mark, and good morning, everyone. Also with me today is Mike Jacobsen, our Chief Accounting Officer. I'll begin today's call with a corporate update, and then Mike will provide an overview of our first quarter financial results. We also have some time reserved for questions after that overview. So, let's start with Omidria. The total revenues for the first quarter were $7.4 million. Our FDA approved ophthalmology product Omidria had a solid quarter with net sales of $7.2 million. During the first quarter, the growth in sell-through or unit vials that our whole sellers actually shift to ASCs and hospitals, increased 20% over the previous quarter. Sales were restrained during January and February, but steeply ramped upward during March. In fact, March alone accounted for nearly 50% of our first quarter. Omidria sell-through from March increased 42% over February and 59% over December 2015, which is inline with our historical quarterly growth rates of 71% from Q2 to Q3 2015 and 74% from Q3 to Q4 2015. Importantly, net revenue per vial sold did not change compared to the previous quarter. In the first quarter, new accounts continued to grow substantially. The number of new accounts added in the first quarter was approximately 30% greater than those added in the fourth quarter of 2015. This is directly tied to the number of ophthalmologist across the country who trialed Omidria, a number that continues to grow week by week. Our research shows that there is a significant difference in the degree to which surgeons appreciate the clinical benefits of Omidria before and after they use the product. We have seen surgeons changed from skeptics to strong advocates when they experienced first hand how the product performs, how it helps their procedures, and how it benefits their patients. Again what…

Thanks, Greg. As Greg noted, overall revenue for the first quarter was $7.4 million, virtually all of which was from Omidria product sales. This is an increase of 11% or $744,000 over the fourth quarter. Our net loss for the first quarter was $20.5 million, or $0.54 per share. This includes non-cash expenses of $4.7 million or $0.12 per share. Now, let’s address some specifics regarding the first quarter of 2016 compared to the fourth quarter of last year. Our reported Omidria revenue for the quarter increased 9% from the fourth quarter, while the sales of Omidria by our wholesalers to the ASEs and the hospitals or as we call it sell through increased by 20% over the fourth quarter. The difference was due to typical first quarter declines in wholesaler inventory. With regard to the pricing of Omidria, the net revenue we received per vial sold remain constant between the fourth and the first quarter. As Greg mentioned earlier, sales ramped up remarkably in the second half of the quarter with the March accounting for nearly 50% of our first quarter revenues. This growth has continued through April and into May. Cost and operating expenses for the first quarter were $26.9 million, an increase of $2.2 million from the fourth quarter, which – and this quarter includes $4.7 million in non-cash charges. The increase in overall cost was primarily related to incremental costs for 721 research and development activities. The increased non-cash stock comp related to annual employee stock option grants and some of the legal cost associated with Par lawsuit. Turning to the balance sheet, as of the end of the first quarter, we had $13.2 million in cash available for our general operations and $10.7 million of restricted cash primarily tied to our debt agreement with Oxford…

Thanks, Mike. Operator, let’s open the call to questions.

Thank you. [Operator Instructions] Our first question comes from Liana Moussatos with Wedbush Securities. Your may begin.

Thank you for taking my questions and congratulations on all your progress.

Thanks, Liana.

Can you tell us about the size of the Middle Eastern market for Omidria and what the revenue split is with ITROM and also can you remind us what are the components of cost of product sales and how should we think about them going forward in 2016.

Yes. Let me first give you the number. There is not a very good number for the Middle East, but it’s roughly about in the territories that we’re talking about $0.5 million procedures annually. With respect to the revenue split, we have not provided that information. What was your – what was the third part of that question Liana.

What are the components of cost of product sales and how should we think about them going forward in 2016.

Sure. Its product that’s obsolete. It’s our shipping costs and it’s also our cost from the 3PL the distributor cost associated with the 3PL. We would consider those largely staying about the same. Total it’s about 5% of sales and we would expect that number to remain pretty standard going forward.

And can you remind us about your cash reserves, you have an ATM in place and anything else.

Yes. We have an ATM in place. As you would expect for cash it’s always the same approaches. Its partnering dollars, its debt and its equity, we are obviously can access, we believe all three of those throughout the year and we expect that again, we don’t need much to become cash flow positive.

Thank you very much.

Thanks, Liana.

Thank you. Our next question comes from Steve Brozak with WBB Securities. You may begin.

Hi good morning Greg and team. And thanks for taking the call. Hey Greg I’m going to dive right in here, because there was something that you looked, I mean you were saying the initial part about the sales increase that you were looking at. You brought in, I think, I had done one third with you folks. And you’ve started to just see a kick up in terms of sales towards the end of the quarter. Can you give any kind of detail as to what the lead time is or typically what you would expect on these new types of sales people, because obviously there seems to be like a different kind of paradigm here you are talking about where in the beginning there are slower observations, but towards the end you are starting to pick it up. And I wanted to know what to read into that, how can explain that and what we can take away from that now and into the future. And I’ve got a follow-up please.

Yes I think, thanks Steve. I think a couple of answers to your question. First, I mean the restrained sales in the first part of the quarter, I think have multiple factors feeding into that. And I went through those, I think in the script and would be happy to touch on those again if you would like. But I think also with respect to your question about really the sales cycle that's about – that remains at about eight to 12, 10 to 12 weeks with respect to how quickly physicians trial, and then from trial move to ordering small amounts and then become really confirmed OMIDRIA users. You're correct in what we did in the first part of the year was change out about a third of the sales force. And they trained in January, hit the field in February. And yes we are now seeing we believe the effects of their efforts, but also just the external factors, the growth that occurs in the procedures being performed during this part of the year and throughout the rest of the year as opposed to the first quarter.

And so following along those lines you've got these folks that have been brought in that seem to have added this acceleration because it isn't de minimus, it's very significant. And the other part obviously people care about is on the reimbursement you're still seeing the same trends in terms of reimbursement and all the questions as far as that goes. Is that also still accurate?

Yes that's accurate Steve yes it is. And you're right the growth rates in the second half of the quarter ramped up steeply. And actually have returned to the same trajectory that we were seeing from Q2 to Q3 and Q3 to Q4 in 2015. So we're quite pleased with that. That growth rate was seen in March, but I think more importantly has been sustained through April and through this first part of May. And again we're pleased with what we're seeing there. It confirms to us our confidence in our ability to achieve cash flow positive status later this year.

Okay and my last question. I guess we're not different than any other bank, we're seeing a lot of activity interest and business development. Licensing deals you just obviously just announced one. With the different number of programs that you've got and I know you can't obviously, we’re not breaking FD. But you're constantly being pinged I'm sure, on different business development, different collaborative deals. I would say that that’s one of the arrows in your quiver in terms of if you were to need additional funding, or creative funding, or any collaborative funding, that that would be something that you would have an option to is that a good way to look at it, given how many programs you've got and how much time there is in a day for you to pursue each of these programs as well?

Oh yes, Steve we don't speak directly about our funding plans or strategies. But you've certainly identified one of the arms which is partnering. And I don't think it would be surprising to anyone to find that there is interest in a number of our programs, frankly including OMS721, OMS527 and other of our programs. That's an option, certainly debt is an option, there are avenues here for us to expand our debt as you might imagine. And then we also always have the third option of equity. So those are the options and that’s where we currently stand. And again we expect that we'll be moving pretty quickly here to achieve that cash flow positive status by year-end.

Well again thank you for taking the question very much. Everybody is looking forward to seeing how the sales ramp in Q2 given the moment you’ve got. So I’ll hop back in the queue. But again thanks and congrats.

Thanks Steve.

Thank you. Our next question is from Tyler Van Buren from Cowen and Company. You may begin.

Hi good morning and congratulations on the momentum that you're experiencing with OMIDRIA at the moment.

Thanks Tyler.

With respect to the second half. Yes.

Yes.

With respect to the second half Q1 acceleration it was very helpful to hear about the factors that were restraining the product early on and then now some of the growth drivers that appear to be sustainable throughout the year. But as we take a step back and look at the overall market opportunity has anything in your eyes changed recently? I just want to get kind of your updated thoughts on the overall market opportunity and potential for this product?

Not at all. In fact – and I'm assuming when you say change, you mean are we more conservative than what we think the product can achieve. The answer to that is no. In fact what we see with respect to what's coming out of the investigator initiated studies, what's coming out of the manuscripts are things that frankly only we believe will drive further adoption of OMIDRIA throughout the cataract surgery field. When we speak to physicians who have actually used the product and I underscore actually have used the product because that's a little different than folks who have never used it and have not seen the benefits firsthand. As I said earlier, in the opening remarks, I believe that there is a meaningful difference between those who actually try the product and have it in their hands. Once they do I think it's difficult for them to go back to anything else. And those are certainly the reports that we get. So our focus is, how do we expand that base of cataract surgeons who are trailing the drug, who are then converting to users. But no in short to your question if anything we're seeing the opportunity just expand. For instance, this manuscript that will be published we expect sometime soon, directed to use of OMIDRIA versus use of topical NSAID pre and post operatively. I don't want to presage those findings. But let's just say should those findings be positive for OMIDRIA and [indiscernible] OMIDRIA can be as effective as pre and post op NSAIDs. The importance of that I think would be quite significant. So if any of the thing we see, we see the opportunity growing.

Yes apologies if wasn’t clear that’s what I was suggesting given the improved dynamics of the opportunity you view it as potentially more significant than what you had originally. Have you given any thoughts on what you think the ultimate peak opportunity might be and if there's any relevant products that could be good comparables out there?

Yes I understand the question. And I'd prefer just to – rather than to project a peak sales number, I think the answer is in part again found in the clinical data. You remember that our Phase III clinical data were pretty constrained with respect to design. So there were no IFIS patients or inter-operative floppy iris syndrome patients, there were no femta second lasers used there were no other more complex components of cataract surgery in those Phase III studies, simply for purposes of standardization. But since the product has been out now in the hands of surgeons in the real world the products being used with femta second laser, it’s being used in IFIS cases, it's being used in pseudoexfoliation cases, all of these cases that were not included in the Phase III program. And the data are consistently and resoundingly positive. So in fact this was one of the themes that was brought out at ASCRS which I believe is wrapping up today. So I think that that should underscore, I think where the product can ultimately, what sort of levels that product can reach.

Great. And just one last question clearly you all are investing a lot in the launch of OMIDRIA and increasing the sales force. How do you all think about potentially adding another product to the bag and in what way might that be possible. Thank you.

Thanks Tyler. Certainly we think about that. We have a dedicated sales force through OMIDRIA that is detailing cataract surgeons in the ASCs and in the HOPDs. It would make sense for us to lever that strength with another product. One might think that we are exploring those opportunities. We don't see ourselves as an ophthalmology company, with the kind of pipeline that we clearly have. But I think adding another product or one or more other products to the bag of our sales representatives, when they're already making those calls would only be cost effective and we're interested in that.

Great thanks again.

Thanks Tyler.

Thank you our next question comes from Jason McCarthy with Maxim Group. You may begin.

Hi Greg congratulations on all the success so far with OMIDRIA and ramping those sales. I want to steer the conversation away from commercial and OMIDRIA’s over to the pipeline. And I was wondering if you could walk us through, I know for OMS721 enrollment will start later this year. Can you give us a sense of how fast you think that trial could enroll? Will there be some interim looks at the data and at what point would you see enough data to be able to commit the filing of BLA? And just in addition to that when can we see some data points from the Phase II HSCT? TMA is in the Phase II in renal disease. Thank you.

Yes thanks Jason. With respect to timelines for Phase III study, and pace of enrollment we are continuing to add sites for that Phase III program and those sites are worldwide, we do expect to be able to enroll that program at a reasonable rate. With respect to the open-label component of it, I mean the advantage of being open-label obviously is the ability to see those data as they come in. Assuming that we're seeing a signal similar to what we have seen in the Phase II study. When we felt like we had enough of those data points. We would expect to take that to the FDA and again discuss the accelerated approval with them. So I'm hoping is that answering your question.

Yes, thank you.

Okay. Now let's turn to your Phase II question which was the HSCT and the renal disease questions. With HSCT, the Phase II data that we’ve already released demonstrated effect of OMS721 and HSCT that becomes very important for a couple of reasons. One is clearly there is no treatment for these patients that develop significant TMAs and can quickly decompensate and then frankly pass away. In fact some of the difficulty just in enrolling that study is getting to these patients quickly enough prior to their demise. But what you see in the Phase II data that we've already released on stem cell. Is that 721 broke, completely broke that TMA. And so we're looking at really two parts to the stem cell program. One is treatment and that's the program that we are currently focused on we are accessing patients broadly. There's a lot of interest out there in the transplant community in 721. And the objective there is to get to them early enough so that we can treat them. And we believe that now we're capable of doing that. And with a few more patients actually our expectation would be to go to the FDA assuming those data are positive, go to the FDA requesting accelerated approval likely breakthrough designation in a Phase III trial. So we don't think we need many more patients in stem cell transplant to do that. The other component of that is the prevention of stem cell transplant. And that’s another program that we are designing here. The importance of that is it has reached through to other diseases. Not just stem cell transplant related TMAs but potentially veno-occlusive disease and graft versus host disease. Turning to the renal question that you had, that program is enrolling quite quickly. And our expectation is that we will have data from that study this year. We frankly do expect and I'm not trying to guide here to an outcome I'm simply telling you what our expectation is that we will see that 721 can limit the need for steroids in the steroid-dependent patients which again would be an important advance one which we would move quickly to discuss with the FDA how to proceed to a Phase III program. So I think that all of those studies are well in hand. They are diseases certainly aHUS is an ultra orphan, the others are orphan diseases. But I think that we have access to the patients. We're developing a strong following within the academic communities and among the clinicians who treat these patients. And I think that all of that will continue to serve us well as we move to accelerate enrollment.

Great. Thanks for taking the questions.

Thanks. Thank you.

Thank you. Our next question is from Sirjay Balenger with Needham and Company. You may begin.

Hi, good morning, Greg.

Hi, Srijay, how are you?

Couple of questions. First on OMIDRIA, can you tell us if there was any channel inventory changes throughout the quarter. And I think you touched upon the reimbursement cycle in a prior question has that stabilized now and do you expect additional shortening of the cycle. And the last one for OMIDRIA any other seasonality effects do you foresee for the rest of the year?

Yes, thanks Sirjay. First with respect to the channel, we were effectively one week down going into the beginning of the year. And probably at normal levels at the end of March, with respect to the sales cycle we're finding that it contracts. But you still have to get folks through the multiple layers of one trial to once trial ordering. First order, which is a smaller order and then from there moving to a confirmed user with larger orders. That process still sort of takes that 8 to 12, 10 to 12 weeks. That I mentioned initially. Your third question was about seasonality I believe and no, the real seasonality is Q1 in cataract surgery. And I think as I mentioned in the comments I think there are a number of components to that. One is just deductibles reset at the beginning of the year and most people don't want to have to write a check for the deductible component of a surgical procedure in one shot. And that's why folks tend not to and this is not specific to cataract surgery it's pretty generalized to surgical procedures. But there's a reticence to incur those costs and surgeries that are performed or scheduled a little later in the year. The other real component on the ophthalmic side is just all of the conferences. In the January early February timeframe and conferences in very nice places ophthalmologists tend to go to very nice places for these conferences which means that they're attractive. But we don't see really any other seasonality other than those that you would normally expect around the holiday seasons et cetera. But even there again because of the deductible issue patients tend to prefer to have those procedures prior to the end of the year, prior to the resetting of deductibles.

Okay. And one last question. It looks like your targets to reach cash flow positive status has changed slightly from the prior update I think in the past you’d said by midyear you know later – you're now saying later this year. What is behind that change – any change?

Well actually, that it wasn't quite by midyear it was by the mid part of the year and that’s there is a large mid part of every year, Sirjay. But so what we're saying is later this year in 2016. That could be in the latter part of the mid part or that could be in just the latter part of the year that we expect to be cash flow positive. I think if you look at the numbers from Q1. And you compare those to what was happening Q3, Q4 what you really see is Q3, Q4 with a nice trajectory. And then all of a sudden you see January and February effectively flattening out. And the reasons for those are the ones that I think we discussed no one can be certain for what they were. But certainly the reasons provided I think make eminent sense. But then what you see is March. You're right back up that trajectory continues or frankly the slope maybe even a little steeper. But and that continues on through April and May. And so when we look at that this is what's really giving us the confidence to say cash flow positive later this year. A small hiatus in January, February, one that we thought might be there to an extent particularly given our turnover of our sales force from the contract to the in-house and the other components. But tell you it was a little concerning when we are watching those numbers and all of a sudden we just kept saying well that's wait and see what happens in March and then March came through and then April continued and May continued after that. So we're pretty confident in the growth rate here what we're seeing is continued utilization by new accounts, which is obviously the important piece here. You've got to grow this market in two ways one by increasing the number of procedures using OMIDRIA by each of the facilities or physicians who currently use OMIDRIA and we've been hitting that very hard and we have additional initiatives which should drive the utilization of OMIDRIA even further in those already using. But frankly it's also you've got to build that base and we're building that base for new accounts every single day. So we're quite pleased with that we'd always like to be doing it better, doing it faster. And that's why we focus new initiatives we're not afraid to try new things. What works we stick with what doesn't. We quickly shed.

Okay, thanks Greg.

Thanks Sirjay.

Thank you. Our next question is from Thomas Yip with FBR and Company. You may begin.

Hey, good morning everyone. Thanks for taking my questions. I’m very glad to hear your progress in OMIDRIA. And you other pipeline assets, my first question pertains to on that 721. Just wondering if you can walk us through what are the final steps before the Phase III aHUS trial can begin enrollment other than ramping up sites?

One more time, Thomas I’m sorry, you are breaking up.

Yes, just can you walk us through what are the steps are there in order for the Phase III 721 trial to ramp up enrollment this year other than opening up sites?

Sure. I mean obviously the most important is enrolling is getting the sites up and running and operational for the Phase III program that is the number one priority for that program. There are still some minor modifications that need to be made to the protocol design its running the protocol through the appropriate IRBs or medical ethics committees but in general, I think we're in pretty good shape.

That's good to hear. I also have a question about little bit on finance side, so your cash flow target does that include potential A24 R&D costs for this year?

Yes, it does. Now when we say cash flow positive remember that the product has been cash flow positive meaning within the – within its program for months now. When we are talking about cash flow positive, we’re talking about the operated additional expenses for the company.

Okay, thanks for that clarification. I have one final question for your 527 asset. When should we expect to see some preclinical data presentation?

Good question. I think that we will be speaking more about 527 as we begin to move it toward the clinic. As I said, there will be a manuscript that will be forth coming around 527, its mechanism of action, the full data set that has been generated. We expect that seminal paper to be published in one of the premier journals. And our expectation is to get that submitted here in the not too distant future.

Okay, sounds good. I’ll look forward to that update. Thanks again for clearing my questions and I’m looking forward to your next update.

Thank you very much.

Thank you. Our next question comes from George Navoiko with Jones Trading. You may begin.

Hi, thank you. Hi, Greg and I welcome Leonard to the company. It’s nice to see the momentum going forward. Couple of quick questions I think, given the time constraints here already. Regarding ARVO and ASCRS as you mentioned a lot of endpoints that you were being monitored and published, but you didn’t mention pain, that was one of Phase III issues. I would imagine that’s also part of the endpoints that you talked about and…

Yes, absolutely. The reduction in post operative pain is clearly one of the – one of the focuses.

Okay. And then with regard to your revenue of about $7.4 million or about that for Omidria, if you divide that by the average cost you end up with treating just so much eye of 20,000 eyes which first of all, accurate, and second of all, I mean that’s a mere fraction of the total potential market, is that correct because that’s somewhere up in the 1 million or 2 million eyes if I remember correctly. And according – and related to that you mentioned some of the higher risk operations that you’re now using in Omidria. Could you – is it also being used a lot in the low risk eyes as well?

Yes. I’ll take those questions in reverse order. Absolutely it’s being used by a good number of surgeons broadly across their practice in simple procedures, in complex procedures as well. So eye pseudoexfoliation other cases that include femtosecond lasers, all of the cases George are amenable and are being used frankly – are using Omidria across all of those. With respect to your question about number of procedures and percentage of total available procedures that can be accessed. You’re right. There is a very large segment of the market that we have not accessed and that’s what we’re focused on accessing.

Okay. Along those lines of reimbursement, you mentioned something like 90% plus of covered lives of the 30 top – I think it’s a 30 top insurers. I mean when you take all that into account who’s left? I mean that sounds like that’s pretty much the entire U.S. population.

Yes. Well, the coverage for Omidria has brought 100% of the Medicare administrative contractors cover it and reimburse for it. As again I said, of the top 30 commercial payers in the U.S. coverage is confirmed for 97% of them. Again that coverage and payment can depend on specific contracts with specific facilities. But yes, the reimbursement has been growing – continues to grow for the product. And then the Omidria share program which stands behind all of that on behalf of the patient, really makes it I think quite a robust program and really protects the patients here. And by way of protecting the patients obviously certainly helps the facilities.

It only sounds to me like you’re getting reimbursement faster than you’re getting the sales reps to the ophthalmologists. Is that fair to say almost, I mean, fewer than which coverage but you’re not – here you’ve still got a lot of ophthalmologists to reach with your detailers.

Not quite sure I understand the question, but reimbursement been picking up quickly, our reps do get to the sites and to the facilities quickly and their objective obviously is to continue to expand the sales and you see it…

[Indiscernible] something called delay concern I guess, is that right?

Yes, right.

And regarding the patent infringement, Greg, your March 2016 patent – the new patents that was granted. What’s the next step there? I mean it seems to me that patent could potentially go up against or I’m not sure we’re talking the legal terms but it could sort of invalidate some of the claims that Par has against Omidria. Can you – I know it’s a legal proceeding underwriting then I will be able to say very much, but is there any clarification you can give regarding that case.

Well, we don’t speak about the legal proceedings more than to say that – we have asserted against Par and we remain very confident in the strength of our patents. I think as we put out recently, we issued a release around our fourth patent that Omeros received on Omidria. And at that time that patent was directed to pieces of prior art that Par had put forth at that time. And I think, again, all of that was blast off by the examiner in the issuance of that patent.

Okay.

Again, I think that this is kind of business as usual for Par. We take it as a compliment that Par feels that this product is worthy of their focus. But we’re very confident in our ability to defend that. That is not something that I lose sleep over at all. It’s in good hands. We’re dealing with that as it needs to be managed. But I really – I got to tell you George, I don’t have undo concerns about that. We’re taking it seriously as we should, but I am very confident that we’ll prevail that our patterns will prevail.

Okay. And then finally like one or two quick questions with 721. Any update on the finished patient?

Other than that the treatment has begun for that patient and to-date the patients tolerating treatment well. But we’re still early in the treatment.

Okay. And regarding the Phase II renal trial, according to clinical trials like how you’ve got a – you’re expecting normally about 50 patients with four conditions. Are you stratifying to get four of each one of the conditions or are you pretty much you’re coming as – enrolling as they come?

Enrolling as they come.

Okay.

Of course we want to have that spread across those four, but we’re enrolling as they come. And we’ll treat each cohort separately.

Okay, great. That’s it, thank you very much, Greg.

Thanks a lot, George.

Thank you. Our next question is from Liana Moussatos with Wedbush Securities. You may begin.

I just have a follow-up question on expecting clinical data releases this year. You mention in 721 Phase II for renal diseases some data from that. And take publications one for 527 mechanism of action, and one for Omidria versus topical NSAID. Are there any other publications or data presentations clinical for this year?

Yes. I mean I think that we’ll be putting out 721 data as you said from our Phase II program or programs. There will be publications on both 721 and 527. I think there will be more data coming out of the GPCR program. So I think that there’s going to be a long line of data and journal articles publications throughout the year.

Thank you very much.

Thanks, Liana.

Thank you. That completes the Q&A part of the call. I’d like to turn the call back over to Dr. Demopulos for closing comments.

Thanks, operator that wraps up our call for today. Thanks again everyone for taking the time to listen in, Omidria sales are growing nicely and the remainder of the year holds a number of exciting milestones for Omeros. As always, we appreciate your continued interest and support. Have a good day. Thank you very much.

Ladies and gentlemen this concludes today’s conference. Thanks for your participation. Have a wonderful day.